Holen Sie sich die Stockscreener-App
0.3469
2.10%
0.00715
Handel nachbörslich:
.33
-0.0169
-4.87%
Schlusskurs vom Vortag:
$0.3398
Offen:
$0.3315
24-Stunden-Volumen:
223.07K
Relative Volume:
0.36
Marktkapitalisierung:
$5.56M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-15.42M
KGV:
-0.1885
EPS:
-1.84
Netto-Cashflow:
$-13.41M
1W Leistung:
-13.28%
1M Leistung:
-24.70%
6M Leistung:
-63.86%
1J Leistung:
-86.23%
1-Tages-Spanne:
$0.3315
$0.35
1-Wochen-Bereich:
$0.31
$0.3649
52-Wochen-Spanne:
$0.31
$2.755
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Firmenname
Indaptus Therapeutics Inc
Sektor
Branche
Telefon
(646) 427-2727
Adresse
3 COLUMBUS CIRCLE, NEW YORK
Vergleichen Sie INDP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
0.3469 | 6.41M | 0 | -15.42M | -13.41M | -1.84 |
|
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Indaptus Therapeutics Inc Aktie (INDP) Neueste Nachrichten
INDP stock touches 52-week low at $0.31 amid sharp annual decline By Investing.com - Investing.com South Africa
INDP stock touches 52-week low at $0.31 amid sharp annual decline - Investing.com Australia
Indaptus Therapeutics (INDP) Advances Clinical Trial with Decoy2 - GuruFocus
Breakthrough Cancer Trial: Indaptus Tests Novel Immunotherapy Combo for Checkpoint Inhibitor Resistant Tumors - Stock Titan
Indaptus Therapeutics (NASDAQ:INDP) Trading Down 1.9% – What’s Next? - Defense World
Indaptus Therapeutics (INDP) Advances Clinical Trials and Expands Patent Portfolio | INDP Stock News - GuruFocus
INDP Faces Funding Needs as Cash Reserves Decline | INDP Stock News - GuruFocus
Indaptus Therapeutics reports Q1 EPS (32c) vs. (45c) last year - TipRanks
Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Indaptus Therapeutics Q1 2025 Financial Results and Corporate Update - TradingView
Indaptus Therapeutics, Inc. SEC 10-Q Report - TradingView
Indaptus Launches Key Cancer Drug Combination Trial as Q1 Cash Drops to $3.9MWhat's Next? - Stock Titan
Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025 - marketscreener.com
Closing Figures Unveiled: Indaptus Therapeutics Inc (INDP) Gain 7.96, Closes at 0.71 - DWinneX
Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit - The Manila Times
Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update - Defense World
Indaptus Therapeutics Inc (NASDAQ: INDP) Stock Is Down -10.94% From Its Low: The Uptrend Is Still On - Stocks Register
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit - The Manila Times
Top Biotech CMO Summit Taps Indaptus Expert to Guide Clinical Trial Excellence Discussion - Stock Titan
Selling Your Indaptus Therapeutics Inc (NASDAQ: INDP) Stock? Here’s What You Need To Know - Stocks Register
Indaptus Therapeutics looks to raise $2.25M in private placement - MSN
Indaptus reports progress in Decoy20 cancer therapy trial By Investing.com - Investing.com South Africa
INDP stock touches 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa
INDP stock touches 52-week low at $0.7 amid market challenges - Investing.com
Indaptus Therapeutics Says New Data on Decoy20 Shows Broad Immune System Activation in Cancer Patients - Marketscreener.com
Indaptus reports progress in Decoy20 cancer therapy trial - Investing.com India
Breakthrough: Indaptus Cancer Drug Successfully Activates Immune System in Weekly Dosing Trial - Stock Titan
Indaptus tests new cancer therapy combination By Investing.com - Investing.com Australia
Indaptus tests new cancer therapy combination - Investing.com India
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab - The Manila Times
Groundbreaking Cancer Trial: Indaptus Combines Novel Decoy20 with Checkpoint Inhibitor - StockTitan
EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors - Benzinga
Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Significant Drop in Short Interest - Defense World
INDAPTUS THERAPEUTICS Earnings Results: $INDP Reports Quarterly Earnings - Nasdaq
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update - The Manila Times
Indaptus Therapeutics reports full-year loss of $1.61 per share -March 13, 2025 at 07:40 am EDT - Marketscreener.com
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results - TradingView
Indaptus Therapeutics Enrolls Over 20 Patients in Phase 1 Trial of Decoy20, Achieving Key Clinical Milestone - Nasdaq
Indaptus Therapeutics, Inc. SEC 10-K Report - TradingView
Registration Is Now Open For Tribe Public’s Webinar Event - GlobeNewswire
Registration Is Now Open For Tribe Public's Webinar Event 'Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025 - The Manila Times
Registration Is Now Open For Tribe Public’s Webinar Event "Keys To The Kingdom: Unlocking The Power Of Your Immune System" Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025 - Nasdaq
Indaptus Therapeutics extends patent portfolio in China, Japan, and Israel - BioSpectrum Asia
Indaptus Therapeutics Expands Patent Portfolio In China, Japan, And Israel, Strengthening Its Intellectual Property For Infectious Disease And Cancer Treatments - Marketscreener.com
Indaptus secures new patents in Asia and Israel for Decoy platform By Investing.com - Investing.com South Africa
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments - The Manila Times
Indaptus secures new patents in Asia and Israel for Decoy platform - Investing.com
Indaptus Therapeutics Secures New Patent Approvals in China, Japan, and Israel for Decoy Platform in HIV and HBV Treatment - Nasdaq
Finanzdaten der Indaptus Therapeutics Inc-Aktie (INDP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
1.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):